Iovance Biotherapeutics (IOVA) Pops 43% on Stellar Q2. Here’s What Comes Next

This is a summary. Read the complete story at Yahoo Finance below.

Related Stories

marketsabout 6 hours ago

This could be the worst year ever for Nike’s stock, with sales set to fall further

The company has faced struggles in China and in its sneaker business.

MarketWatch

marketsabout 6 hours ago

Here’s who’s joining the S&P 500 in the index’s latest shakeup

Twilio gets the nod, as current component Warner Bros Discovery is due to merger with Paramount.

MarketWatch

marketsabout 8 hours ago

The hidden silver lining of high interest rates: safer, cheaper retirement income

Annuity payout rates are closely tied to interest rates

MarketWatch